Related Experiment Video
Updated: Jan 10, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Pulmonary toxicity of immune-checkpoint inhibitors
Cédric Mahiat1, Jacques Cadranel1, Vincent Fallet1
1Department of Pulmonology and Thoracic Oncology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) and Sorbonne University, Paris, France.
Abstract:
Immune checkpoint inhibitor-related pneumonitis (ICI-P) is an uncommon but serious immune-related adverse event, representing the leading cause of treatment-related mortality among patients receiving immune checkpoint inhibitors (ICIs). Prompt recognition and effective management are therefore critical. This review summarizes current data on the epidemiology, clinical and radiological features of ICI-P, and offers practical recommendations for its management, including considerations for ICI rechallenge. Particular attention is given to high-risk populations, such as patients with prior thoracic radiotherapy or underlying interstitial lung disease.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Tumor Immunotherapy
Other Pulmonary Disorders

